Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Parkinsonism Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cholinergic Nicotinic Receptors and Cognition in PD

NCT02076295
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Not applicable Interventional Results available

Genetic Influences on Response to Gait Rehabilitation in Parkinson's Disease

NCT03607695
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Gait training
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

NCT00321854
View directory record Official record
Conditions
Parkinson Disease
Interventions
pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years to 79 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
32
States / cities
Brimingham, Alabama • Scottsdale, Arizona • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Telephone-Based Counseling for Depression in Parkinson's Disease

NCT02505737
View directory record Official record
Conditions
Depression, Parkinson's Disease
Interventions
TH-CBT, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 29, 2026, 5:54 PM EDT
Terminated Not applicable Interventional Results available

A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease

NCT02134795
View directory record Official record
Conditions
Parkinson's Disease
Interventions
TNM Device
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 29, 2026, 5:54 PM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT01968031
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Istradefylline 40 mg, Istradefylline 20 mg, Placebo
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
30 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

NCT00381472
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
28
States / cities
Birmingham, Alabama • Northridge, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 29, 2026, 5:54 PM EDT
Recruiting Not applicable Interventional

Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs

NCT07221266
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Guided Cycling, Non-Contact Boxing, Traditional Physical Therapy Program (Standard of Care)
Behavioral
Lead sponsor
University of Texas, El Paso
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa

NCT00134966
View directory record Official record
Conditions
Parkinson's Disease
Interventions
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Reseda, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 29, 2026, 5:54 PM EDT
Active, not recruiting Not applicable Interventional

The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy

NCT03582891
View directory record Official record
Conditions
Parkinson Disease, Dystonia
Interventions
Summit RC+S for Motor, 8-week pilot trial of Closed-loop vs. Open-loop Stimulation, Summit RC+S for Sleep
Device · Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 29, 2026, 5:54 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
35 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of DA-9805 for Parkinson's Disease

NCT03189563
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DA-9805 45mg, DA-9805 90mg, Placebo
Drug · Other
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
30 Years to 79 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 29, 2026, 5:54 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

High Fiber in Parkinson's Disease

NCT04976959
View directory record Official record
Conditions
Parkinson Disease
Interventions
High Fiber supplement
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 29, 2026, 5:54 PM EDT
Not yet recruiting No phase listed Observational

Remote Monitoring in Progressive Supranuclear Palsy (PSP)

NCT04753320
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 2 Interventional Results available

Image Parkinson's Disease Progression Study

NCT02789020
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo, Magnetic Resonance Imaging, functional Magnetic Resonance Imaging, Physical Function Performance Test
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 77 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

NCT01953523
View directory record Official record
Conditions
Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions
Administration of autologous adipose derived SVF
Procedure
Lead sponsor
Elliot Lander
Industry
Eligibility
16 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

NCT04292223
View directory record Official record
Conditions
Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Not applicable Interventional

Non-contact Boxing Training and Traditional Therapeutic Exercise for Persons With Parkinson's Disease

NCT01014663
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Traditional Therapeutic Exercise, Non-Contact Boxing Training
Behavioral
Lead sponsor
University of Indianapolis
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 4 Interventional Results available

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

NCT01018264
View directory record Official record
Conditions
Overactive Bladder in Parkinson's Disease
Interventions
solifenacin succinate (VESIcare), placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 1Phase 2 Interventional

Chinese Exercise Modalities in Parkinson's Disease

NCT00029809
View directory record Official record
Conditions
Parkinson Disease
Interventions
Chinese exercise modalities
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 29, 2026, 5:54 PM EDT
Terminated No phase listed Observational

Imaging a Cholinergic Biomarker of Cognition in Parkinson's Disease

NCT05034263
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 29, 2026, 5:54 PM EDT
Completed No phase listed Observational

Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3

NCT03079037
View directory record Official record
Conditions
Parkinson Disease
Interventions
Stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 29, 2026, 5:54 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

NCT00594386
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
37
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 29, 2026, 5:54 PM EDT